Non-invasive delivery strategies for biologics

Nat Rev Drug Discov. 2019 Jan;18(1):19-40. doi: 10.1038/nrd.2018.183. Epub 2018 Nov 30.


Biologics now constitute a significant element of available medical treatments. Owing to their clinical and commercial success, biologics are a rapidly growing class and have become a dominant therapeutic modality. Although most of the successful biologics to date are drugs that bear a peptidic backbone, ranging from small peptides to monoclonal antibodies (~500 residues; 150 kDa), new biologic modalities, such as nucleotide-based therapeutics and viral gene therapies, are rapidly maturing towards widespread clinical use. Given the rise of peptides and proteins in the pharmaceutical landscape, tremendous research and development interest exists in developing less-invasive or non-invasive routes for the systemic delivery of biologics, including subcutaneous, transdermal, oral, inhalation, nasal and buccal routes. This Review summarizes the current status, latest updates and future prospects for such delivery of peptides, proteins and other biologics.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Administration, Inhalation
  • Administration, Intranasal
  • Administration, Oral
  • Biological Products / administration & dosage*
  • Drug Administration Routes*
  • Drug Carriers / chemistry*
  • Drug Delivery Systems*
  • Drug Stability
  • Humans


  • Biological Products
  • Drug Carriers